Clinical isolates of Mycobacterium abscessus in Guangzhou area most possibly from the environmental infection showed variable susceptibility

Chinese Medical Journal

Volumn 126, Issue 10, 2013, Pages 1878-1883

  Zhuo, Feng Lin ^a   Sun, Zhao Gang ^b   Li, Chuan You ^b   Liu, Zhi Hui ^c   Cai, Lin ^a   Zhou, Cheng ^a   Zhang, Jian Zhong ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c GUANGZHOU CHEST HOSPITAL   (China)

Author keywords

Genetic diversity; Mycobacterium abscessus; Prevalence; Susceptibility

Indexed keywords

AMIKACIN; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; HEAT SHOCK PROTEIN 65; IMIPENEM; OFLOXACIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BROTH DILUTION; CHEMICAL ANALYSIS; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; DISEASE TRANSMISSION; DNA EXTRACTION; GAS CHROMATOGRAPHY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; QUALITY CONTROL; RANDOM AMPLIFIED POLYMORPHIC DNA; RESTRICTION MAPPING; SPECIES IDENTIFICATION;

AMIKACIN; ANTI-BACTERIAL AGENTS; CEFOXITIN; CHINA; CHROMATOGRAPHY, GAS; CIPROFLOXACIN; CLARITHROMYCIN; IMIPENEM; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM; POLYMERASE CHAIN REACTION; RANDOM AMPLIFIED POLYMORPHIC DNA TECHNIQUE;

EID: 84877850366     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20122495     Document Type: Article

References (32)

1. Wang HX, Yue J, Han M, Yang JH, Gao RL, Jing LJ, et al. Nontuberculous mycobacteria: susceptibility pattern and prevalence rate in Shanghai from 2005 to 2008. Chin Med J 2010; 123: 184-187.
2. Bechara C, Macheras E, Heym B, Pages A, Auffret N. Mycobacterium abscessus skin infection after tattooing: first case report and review of the literature. Dermatology 2010; 221: 1-4.
3. Kim HS, Park IH, Seo SH, Han I, Cho HS. Multifocal infection of mycobacterium other than tuberculosis mimicking a soft tissue tumor of the extremity. Orthopedics 2011; 34: e952-e955.
4. Agarwal A, Maloney RW. Mycobacterium abscessus outbreak after rhytidectomies performed in an outpatient surgery center. Plast Reconstr Surg 2011; 128: 85e-86e.
5. Gan H, Ouyang Q, Bu H, Li S, Chen D, Li G, et al. Value of polymerase chain reaction assay in diagnosis of intestinal tuberculosis and differentiation from Crohn's disease. Chin Med J 1995; 108: 215-220.
6. Swenson JM, Wallace RJ Jr, Silcox VA, Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 1985; 28: 807-811.
7. Wallace RJ Jr, Brown B, Onyi G. Susceptibilities of Mycobacterium fortuim biovar. fortuim and the two subgroups of Mycobacterium chelonae to imipenem, cefemetazole, cefoxitin, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1991; 35: 773-775.
8. Yang SC, Hsueh PR, Lai HC, Teng LJ. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother 2003; 47: 1958-1962.
9. Gayathri R, Therese KL, Deepa P, Mangai S, Madhavan HN. Antibiotic susceptibility pattern of rapidly growing mycobacteria. J Postgrad Med 2010; 56: 76-78.
10. Griffith DE, Aksamit T, Brown-Elliott BA, Daley C, Gordin F, Holland SM, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
11. Brown-Elliott BA, Wallace JR Jr. Clarithromycin resistance in Mycobacterium abscessus. J Clin Microniol 2001; 39:2745.
12. Wallace RJ Jr, Meier A, Brown BA, Zhang Y, Sander P, Onyi GO, et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother 1996; 40: 1676-1681.
13. Wu LZ, Huang JL, Zhang YL, Cai XS, Guan P. Identification of mycobacterium species and analysis of drug susceptibility of mycobacteria isolated from 2001 to 2004 in Guangzhou. J Chin Antitubercul Assoc (Chin) 2006; 8: 170-173.
14. Wu LZ, Li YG, Luo YL, Tan SY, Zhang YB, Cai XS. Species identification and drug susceptibility test analysis of 4587 strains of Myobacterium. Chin J Tuberc Respir Dis (Chin) 2003; 26: 105-106.
15. Jonsson BE, Gilljam M, Lindblad A, Ridell M, Wold AE, Welinder-Olsson C. Molecular epidemiology of Mycobacterium abscessus, with focus on cystic fibrosis. J Clin Microniol 2007; 45: 1497-1504.
16. Zhang Y, Rajagopalan M, Brown BA, Wallace RJ Jr. Randomly amplified polymorphic DNA PCR for comparison of Mycobacterium abscessus strains from nosocomial outbreaks. J Clin Microniol 1997; 35: 3132-3139.
17. Liu ZH, Cai XS, Zhu PB, Guan P, Xu WH, Wu LZ. Study on species identification of Mycobacteria by gas chromatography analysis of whole-cell fatty acid. Chin J Tuberc Respir Dis (Chin) 2005; 28: 403-406.
18. Metchock BG, Nolte FS, Wallace RJ Jr. Mycobacterium. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, and Yolken RH, ed. Manual of Clinical Microbiology. 7th ed. Washington, D.C.: ASM Press; 1999: 399-437.
19. Brunello F, Liqozzi M, Cristelli E. Identification of 54 mycobacterial species by PCR-restriction fragment length polymorphism analysis of the hsp65 gene. J Clin Microbiol 2001; 39: 2799-2806.
20. Dauendorffer JN, Guillemin I, Aubry A, Truffot-Pernot C, Sougakoff W, Jarlier V, et al. Identification of mycobacterial species by PCR sequencing of quinolone resistance-determining regions of DNA gyrase genes. J Clin Microbiol 2003; 41: 1311-1315.
21. National Committee for Clinical Laboratory Standards. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; Approved Standard. Wayne, PA: NCCLS, Document No. M24-A. 2003.
22. Wallace RJ Jr, Bedsole G, Sumter G, Sanders CV, Steele LC, Brown BA, et al. Activities of ciprofloxacin and ofloxacin against rapidly mycobacteria with demonstration of acquired resistance single-drug therapy. Antimicrob Agents Chemother 1990; 34: 65-70.
23. Koh WJ, Kwon OJ, Jeon K, Kim TS, Lee KS, Park YK, et al. Clinical significance of nontuberculous mycobacteria isolated from respiratory specimens in Korea. Chest 2006; 129: 341-348.
24. Foo H, van Hal S, Jelfs P, Gilbert GL. Antimicrobial resistance in non-tuberculous mycobacteria in New South Wales, 2002- 2008. Int J Antimicrob Agents 2009; 34: 182-184.
25. Legrand E, Radegonde N, Goh KS, Rastogi N. A pulsed-field gel electrophoresis study of Mycobacterium fortuitum in a Caribbean setting underlines high genetic diversity of the strains and excludes nosocomial outbreaks. Int J Med Microbiol 2002; 292: 51-57.
26. Park S, Kim S, Park EM, Kim H, Kwon OJ. In vitro antimicrobial Susceptibility of Mycobacterium abscessus in Kero. J Korean Med Sci 2008; 23: 49-52.
27. Simmon KE, Pounder JI, Greene JN, Walsh F, Anderson CM, Cohen S, et al. Identification of an emerging pathogen, Mycobacterium massiliense, by rpoB sequencing of clinical isolates collected in the United States. J Clin Microbiol 2007; 45: 1978-1980.
28. Huang TS, Lee SS, Hsueh PR, Tsai HC, Chen YS, Wann SR, et al. Antimicrobial resistance of rapidly growing mycobacteria in western Taiwan: SMART program 2002. J Formos Med Assoc 2008; 107: 281-287.
29. Woods GL, Bergmann JS, Witebsky FG, Gary A. Multisite reproducibility of results Obtained by the broth microdilution method for susceptibility testing of mycobacterium abscessus, mycobacterium chelonae, and Mycobacterium fortuitum. J Clin Microbiol 1999; 37: 1676-1682.
30. American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997; 156: 1-25.
31. Miyasaka T, Kunishima H, Komatsu M, Tamai K. In vitro efficacy of imipenem in combination with six antimicrobial agents against M. abscessus. Int J Antimicrob Agents 2007; 30: 255-258.
32. Kevin AN, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chem 2009; 53: 1367-1376.